1 Weak Link at This Big Pharma

Eli Lilly , one of the biggest drugmakers in the world, continues to face headwinds as two of its top-selling pharmaceuticals are set to lose patent protection this year. However, one of its billion dollar blockbusters from 2012 --the antipsychotic drug Zyprexa -- has already lost patent protection. How has this expiration affected Eli Lilly's total business, and are there any parallels to one of its competitors in this space, beleaguered pharma company AstraZeneca ? Health care analyst Max Macaluso dives into this issue in the following video.

Can Eli Lilly defeat the patent cliff?
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.

The article 1 Weak Link at This Big Pharma originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.